Driehaus Capital Management’s Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 CLDI.WS Stock Holding History

Driehaus Capital Management's CLDI.WS Position: Q4 2024 in Review

Driehaus Capital Management sold out of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) in Q4 2024, closing a stake of 750,000 shares — an estimated $9.3K sold.

Driehaus Capital Management first reported a position in CLDI.WS in Q3 2024 and held it in 1 quarter. The position peaked at $9.3K in Q3 2024. 1 fund tracked by Wall St. Rank holds CLDI.WS as of Q4 2024.

• Driehaus Capital Management reported no remaining Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position as of Q4 2024 after selling out during the quarter.
• Driehaus Capital Management sold 750,000 Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 shares in Q4 2024, an estimated $9.3K.
• Driehaus Capital Management first reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in Q3 2024 and held it in 1 quarter.
• Driehaus Capital Management's Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position peaked at $9.3K in Q3 2024.
• 1 fund tracked by Wall St. Rank held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 as of Q4 2024.

Based on Driehaus Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.